Real-world outcomes of patients with neuroendocrine liver metastases treated with trans-arterial radioembolization: Results from CIRT, a large European prospective multi-centre observational study

#3189

Introduction: Trans-arterial radioembolization (TARE) is a treatment option for patients with liver dominant metastases from neuroendocrine tumors (mNET). The CIRSE Registry for SIR-Spheres Therapy (CIRT) is a European prospective multi-centre observational study conducted by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Aim(s): To evaluate the clinical outcomes of patients treated with TARE with SIR-Spheres Y90 resin microspheres for mNET in the multi-institutional real-life clinical setting.

Materials and methods: Patients were enrolled prospectively between Jan 2015 and Dec 2017. Eligible patients were adults treated with TARE with Y-90 resin microspheres for mNET. Baseline characteristics and treatment-related data were collected; follow-up data was collected every 3 months for 24 months including overall survival (OS), (hepatic) progression-free survival [(h)PFS] and safety data.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Helmberger T

Authors: Helmberger T, Schaefer N, Pech M, Pfammatter T, Maleux G,

Keywords: liver metastases, observational study, yttrium-90, trans-arterial radioembolization, registry, therapeutic embolization, SIRT,